Research progress of FLT3 inhibitors and drug resistance mechanisms in acute myeloid leukemia / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
;
(12): 90-98, 2024.
Artículo
en Chino
| WPRIM
| ID: wpr-1014565
ABSTRACT
The FMS-like tyrosine kinase 3 (FLT3) gene mutation is the most common genetic mutation in acute myeloid leukemia (AML) and is associated with poor prognosis. Various targeted inhibitors have been developed for FLT3 mutations and have shown promising clinical efficacy. However, the emergence of resistance poses new challenges for targeted therapy in AML. This article provides an overview of the pathological and prognostic role of FLT3 mutations in AML, the current research progress on commonly used FLT3 inhibitors (type I and type II), the mechanisms of FLT3 inhibitor resistance, and strategies for overcoming resistance.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Clinical Pharmacology and Therapeutics
Año:
2024
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS